HF
SNDX icon

HRT Financial’s Syndax Pharmaceuticals SNDX Stock Holding History

HRT Financial’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.94M Buy
363,147
+274,243
+308% +$5.7M 0.01% 886
2026
Q1 		$2.08M Buy
+88,904
New +$1.93M 0.01% 1593
2025
Q4 		– Sell
-148,139
Closed -$2.28M – 3972
2025
Q3 		$2.28M Buy
148,139
+21,028
+17% +$275K 0.01% 1074
2025
Q2 		$1.19M Sell
127,111
-17,923
-12% -$197K 0.01% 1188
2025
Q1 		$1.78M Buy
145,034
+40,154
+38% +$566K 0.01% 860
2024
Q4 		$1.39M Buy
104,880
+51,454
+96% +$881K 0.01% 911
2024
Q3 		$1.03M Buy
+53,426
New +$1.1M 0.01% 1226
2023
Q4 		– Sell
-24,009
Closed -$348K – 3016
2023
Q3 		$348K Buy
24,009
+13,258
+123% +$251K ﹤0.01% 1589
2023
Q2 		$225K Buy
+10,751
New +$224K ﹤0.01% 1782
2022
Q2 		– Sell
-43,145
Closed -$749K – 3669
2022
Q1 		$749K Buy
+43,145
New +$726K 0.01% 1262

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

HRT Financial's SNDX Position: Q2 2026 in Review

HRT Financial increased its Syndax Pharmaceuticals (SNDX) stake by 308% in Q2 2026, buying an estimated $5.7M and bringing the position to 363,147 shares worth $7.94M. The position accounts for 0.01% of the portfolio, ranked #886.

HRT Financial first reported a position in SNDX in Q1 2022 and has held it in 10 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • HRT Financial held 363,147 shares of Syndax Pharmaceuticals worth $7.94M as of Q2 2026.
  • HRT Financial bought 274,243 Syndax Pharmaceuticals shares in Q2 2026, an estimated $5.7M.
  • Syndax Pharmaceuticals made up 0.01% of HRT Financial's portfolio in Q2 2026, its #886 holding.
  • HRT Financial first reported a position in Syndax Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.